Advertisement

HCV-Related Mortality Among HIV/HCV Co-infected Patients: The Importance of Behaviors in the HCV Cure Era (ANRS CO13 HEPAVIH Cohort)

  • Melina Erica Santos
  • Camelia Protopopescu
  • Philippe Sogni
  • Issifou Yaya
  • Lionel Piroth
  • François Bailly
  • Fabienne Marcellin
  • Laure Esterle
  • Linda Wittkop
  • Eric Rosenthal
  • Philippe Morlat
  • Perrine Roux
  • Wildo Navegantes de Araujo
  • Dominique Salmon-Ceron
  • Maria Patrizia CarrieriEmail author
  • the ANRS CO13 HEPAVIH Study Group
Original Paper

Abstract

Mortality among individuals co-infected with HIV and hepatitis C virus (HCV) is relatively high. We evaluated the association between psychoactive substance use and both HCV and non-HCV mortality in HIV/HCV co-infected patients in France, using Fine and Gray’s competing-risk model adjusted for socio-demographic, clinical predictors and confounding factors, while accounting for competing causes of death. Over a 5-year median follow-up period, 77 deaths occurred among 1028 patients. Regular/daily cannabis use, elevated coffee intake, and not currently smoking were independently associated with reduced HCV-mortality (adjusted sub-hazard ratio [95% CI] 0.28 [0.10–0.83], 0.38 [0.15–0.95], and 0.28 [0.10–0.79], respectively). Obesity and severe thinness were associated with increased HCV-mortality (2.44 [1.00–5.93] and 7.25 [2.22–23.6] versus normal weight, respectively). Regular binge drinking was associated with increased non-HCV-mortality (2.19 [1.10–4.37]). Further research is needed to understand the causal mechanisms involved. People living with HIV/HCV co-infection should be referred for tobacco, alcohol and weight control interventions and potential benefits of cannabis-based therapies investigated.

Keywords

Behavior Substance use Hepatitis C HIV Mortality 

Notes

Acknowledgements

English review: Jude Sweeney. Patients in the HEPAVIH Cohort. Scientific Committee of the ANRS CO13 HEPAVIH Study Group: D. Salmon (co-Principal investigator), L. Wittkop (co-Principal Investigator), P. Sogni (co-Principal Investigator), L. Esterle (project manager), P. Trimoulet, J. Izopet, L. Serfaty, V. Paradis, B. Spire, P. Carrieri, M.A. Valantin, G. Pialoux, J. Chas, I. Poizot-Martin, K. Barange, A. Naqvi, E. Rosenthal, A. Bicart-See, O. Bouchaud, A. Gervais, C. Lascoux-Combe, C. Goujard, K. Lacombe, C. Duvivier, D. Vittecoq, D. Neau, P. Morlat, F. Bani-Sadr, L. Meyer, F. Boufassa, S. Dominguez, B. Autran, A.M. Roque, C. Solas, H. Fontaine, D. Costagliola, L. Piroth, A. Simon, D. Zucman, F. Boué, P. Miailhes, E. Billaud, H. Aumaître, D. Rey, G. Peytavin, V. Petrov-Sanchez, A. Pailhé. Clinical Centres (ward/participating physicians): APHP Cochin, Paris (Médecine Interne et Maladies Infectieuses: D. Salmon, R. Usubillaga; Hépato-gastro-entérologie: P. Sogni; Anatomo-pathologie: B. Terris; Virologie :P. Tremeaux); APHP Pitié-Salpétrière, Paris (Maladies Infectieuses et Tropicales: C. Katlama, M.A. Valantin, H. Stitou; Hépato-gastro-entérologie: Y. Benhamou; Anatomo-pathologie: F. Charlotte; Virologie: S. Fourati); APHP Pitié-Salpétrière, Paris (Médecine Interne: A. Simon, P. Cacoub, S. Nafissa); APHM Sainte-Marguerite, Marseille (Service d’Immuno-Hématologie Clinique: I. Poizot-Martin, O. Zaegel, H. Laroche; Virologie: C. Tamalet); APHP Tenon, Paris (Maladies Infectieuses et Tropicales: G. Pialoux, J. Chas,; Anatomo-pathologie: P. Callard, F. Bendjaballah; Virologie: C. Le Pendeven); CHU Purpan, Toulouse (Maladies Infectieuses et Tropicales: B. Marchou; Hépato-gastro-entérologie: L. Alric, K. Barange, S. Metivier; Anatomo-pathologie: J. Selves; Virologie: F. Larroquette); CHU Archet, Nice (Médecine Interne: E. Rosenthal; Infectiologie: A. Naqvi, V. Rio; Anatomo-pathologie: J. Haudebourg, M.C. Saint-Paul; Virologie: C. Partouche); APHP Avicenne, Bobigny (Médecine Interne – Unité VIH: O. Bouchaud; Anatomo-pathologie: M. Ziol; Virologie: Y. Baazia); Hôpital Joseph Ducuing, Toulouse (Médecine Interne: M. Uzan, A. Bicart-See, D. Garipuy, M.J. Ferro-Collados; Anatomo-pathologie: J. Selves; Virologie: F. Nicot); APHP Bichat – Claude-Bernard, Paris (Maladies Infectieuses :, A. Gervais, Y. Yazdanpanah; Anatomo-pathologie: H. Adle-Biassette; Virologie: G. Alexandre); APHP Saint-Louis, Paris (Maladies infectieuses: C. Lascoux-Combe, J.M. Molina,; Anatomo-pathologie: P. Bertheau,; Virologie :M.L. Chaix, C. Delaugerre, S. Maylin); APHP Saint-Antoine (Maladies Infectieuses et Tropicales :, K. Lacombe, J. Bottero; J. Krause P.M. Girard, Anatomo-pathologie: D. Wendum, P. Cervera, J. Adam; Virologie: C. Viala); APHP Bicêtre, Paris (Médecine Interne: C. Goujard, Y. Quertainmont, E. Teicher; Virologie: C. Pallier; Maladies Infectieuses: D. Vittecoq); APHP Necker, Paris (Maladies Infectieuses et Tropicales: O. Lortholary, C. Duvivier, C. Rouzaud, J. Lourenco, F. Touam, C. Louisin: Virologie: V. Avettand-Fenoel, A. Mélard); CHU Pellegrin, Bordeaux (Maladies Infectieuses et Tropicales: D. Neau, A. Ochoa, E. Blanchard, S. Castet-Lafarie, C. Cazanave, D. Malvy, M. Dupon, H. Dutronc, F. Dauchy, L. Lacaze-Buzy; Anatomo-pathologie: P. Bioulac-Sage; Virologie: P. Trimoulet, S. Reigadas); Hôpital Saint-André, Bordeaux (Médecine Interne et Maladies Infectieuses: Médecine Interne et Maladies Infectieuses: P. Morlat, D. Lacoste, F. Bonnet, N. Bernard, M. Hessamfar, J, F. Paccalin, C. Martell, M. C. Pertusa, M. Vandenhende, P. Merciéer, D. Malvy, T. Pistone, M.C. Receveur, M. Méchain, P. Duffau, C Rivoisy, I. Faure, S. Caldato; Anatomo-pathologie: P. Bioulac-Sage; Virologie: P. Trimoulet, S. Reigadas); Hôpital du Haut-Levêque, Bordeaux (Médecine Interne: J.L. Pellegrin, J.F. Viallard, E. Lazzaro, C. Greib; Anatomo-pathologie: P. Bioulac-Sage; Virologie: P. Trimoulet, S. Reigadas); Hôpital FOCH, Suresnes (Médecine Interne: D. Zucman, C. Majerholc; Virologie: E. Farfour); APHP Antoine Béclère, Clamart (Médecine Interne: F. Boué, J. Polo Devoto, I. Kansau, V. Chambrin, C. Pignon, L. Berroukeche, R. Fior, V. Martinez; Virologie: C. Deback); CHU Henri Mondor, Créteil (Immunologie Clinique: Y. Lévy, S. Dominguez, J.D. Lelièvre, A.S. Lascaux, G. Melica); CHU Hôtel Dieu, Nantes (Maladies Infectieuses et Tropicales: E. Billaud, F. Raffi, C. Allavena, V. Reliquet, D. Boutoille, C. Biron; Virologie: A. Rodallec, L. Le Guen); Hôpital de la Croix Rousse, Lyon (Maladies Infectieuses et Tropicales: P. Miailhes, D. Peyramond, C. Chidiac, F. Ader, F. Biron, A. Boibieux, L. Cotte, T. Ferry, T. Perpoint, J. Koffi, F. Zoulim, F. Bailly, P. Lack, M. Maynard, S. Radenne, M. Amiri; Virologie: C. Scholtes, T.T. Le-Thi); CHU Dijon, Dijon (Département d’infectiologie :, L. Piroth, P. Chavanet M. Duong Van Huyen, M. Buisson, A. Waldner-Combernoux, S. Mahy, R. Binois, A.L. Simonet-Lann, D. Croisier-Bertin); CH Perpignan, Perpignan (Maladies infectieuses et tropicales: H. Aumaître); CHU Robert Debré, Reims (Médecine interne, maladies infectieuses et immunologie clinique: F. Bani-Sadr, D. Lambert, Y Nguyen, J.L. Berger); CHRU Strasbourg (Le Trait d’Union: D Rey, M Partisani, ML Batard, C Cheneau, M Priester, C Bernard-Henry, E de Mautort, Virologie: P Gantner et S Fafi-Kremer), APHP Bichat-Claude Bernard (Pharmacologie: G. Peytavin). Data collection: F. Roustant, I. Kmiec, L. Traore, S. Lepuil, S. Parlier, V. Sicart-Payssan, E. Bedel, F. Touam, C. Louisin, M. Mole, C. Bolliot, M. Mebarki, A. Adda-Lievin, F.Z. Makhoukhi, O. Braik, R. Bayoud, M.P. Pietri, V. Le Baut, D. Bornarel, C. Chesnel, D. Beniken, M. Pauchard, S. Akel, S. Caldato, C. Lions, L. Chalal, Z. Julia, H. Hue, A. Soria, M. Cavellec, S. Breau, A. Joulie, P. Fisher, C. Ondo Eyene, S. Ogoudjobi, C. Brochier, V. Thoirain-Galvan. Management, statistical analyses: E. Boerg, P. Carrieri, V. Conte, L. Dequae-Merchadou, M. Desvallees, N. Douiri, L. Esterle, C. Gilbert, S. Gillet, R. Knight, F. Marcellin, L. Michel, M. Mora, C. Protopopescu, P. Roux, B. Spire, S. Tezkratt, I. Yaya, T. Barré, T. Rojas Rojas, V. Villes, M. Baudoin, M. Santos.

Author Contributions

Study concept and design: MPC, CP, DSC. Acquisition of data: LW, LE, LP, FB, ER, PM, PS, DSC. Analysis and interpretation of data: CP, MES, MPC. Drafting of the manuscript: MES, MPC, CP, FM. Critical revision of the manuscript for important intellectual content: MPC, FM, DSC, WNA, LW, LE, ER, PS, PM, IY, PR, LP, FB. Statistical analysis: CP. Obtained funding: LW, MPC. Administrative, technical, or material support: FM, LE. Study supervision: MPC. All authors approved the final revised version of the manuscript.

Funding

ANRS (France Recherche Nord & sud Sida-hiv Hépatites).

References

  1. 1.
    Focà E, Fabbiani M, Prosperi M, Quiros Roldan E, Castelli F, Maggiolo F, et al. Liver fibrosis progression and clinical outcomes are intertwined: role of CD4 + T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: a MASTER cohort study. Medicine. 2016;95:e4091.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Rosenthal E, Roussillon C, Salmon-Céron D, Georget A, Hénard S, Huleux T, et al. Liver-related deaths in HIV-infected patients between 1995 and 2010 in France: the Mortavic 2010 study in collaboration with the Agence Nationale de Recherche sur le SIDA (ANRS) EN 20 Mortalité 2010 survey. HIV Med. 2015;16:230–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Rallón N, García M, García-Samaniego J, Rodríguez N, Cabello A, Restrepo C, et al. HCV coinfection contributes to HIV pathogenesis by increasing immune exhaustion in CD8 T-cells. PLoS ONE. 2017;12:e0173943.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Bruno S, Di Marco V, Iavarone M, Roffi L, Boccaccio V, Crosignani A, et al. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response. Liver Int. 2017;37:1526–34.CrossRefPubMedGoogle Scholar
  5. 5.
    Gast KB, Tjeerdema N, Stijnen T, Smit JWA, Dekkers OM. Insulin resistance and risk of incident cardiovascular events in adults without diabetes: meta-analysis. PLoS ONE. 2012;7:e52036.  https://doi.org/10.1371/journal.pone.0052036.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Cerrato E, Calcagno A, D’Ascenzo F, Biondi-Zoccai G, Mancone M, Grosso Marra W, et al. Cardiovascular disease in HIV patients: from bench to bedside and backwards. Open Hear. 2015;2:e000174.CrossRefGoogle Scholar
  7. 7.
    Palella FJ Jr, Phair JP. Cardiovascular disease in HIV infection. Curr Opin HIV AIDS. 2011;6:266–71.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Cacoub P, Dabis F, Costagliola D, Almeida K, Lert F, Piroth L, et al. Burden of HIV and hepatitis C co-infection: the changing epidemiology of hepatitis C in HIV-infected patients in France. Liver Int. 2015;35:65–70.CrossRefPubMedGoogle Scholar
  9. 9.
    Morlat P, Roussillon C, Henard S, Salmon D, Bonnet F, Cacoub P, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS. 2014;28:1181–91.CrossRefPubMedGoogle Scholar
  10. 10.
    Rosenthal E, Salmon-Céron D, Lewden C, Bouteloup V, Pialoux G, Bonnet F, et al. Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 Study in collaboration with the Mortalité 2005 survey, ANRS EN19). HIV Med. 2009;10:282–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Costagliola D, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the “Mortalité 2000 and 2005” surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr. 2008;48:590–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Weill-Barillet L, Pillonel J, Semaille C, Léon L, Le Strat Y, Pascal X, et al. Hepatitis C virus and HIV seroprevalences, sociodemographic characteristics, behaviors and access to syringes among drug users, a comparison of geographical areas in France, ANRS-Coquelicot 2011 survey. Rev Epidemiol Sante Publique. 2016;64(4):31–312.CrossRefGoogle Scholar
  13. 13.
    Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen KJ, et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS ONE. 2014;9:e103345.  https://doi.org/10.1371/journal.pone.0103345.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Virlogeux V, Zoulim F, Pugliese P, Poizot-Martin I, Valantin MA, Cuzin L, et al. Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination. BMC Med. 2017;15:1–11.CrossRefGoogle Scholar
  15. 15.
    Carrieri MP, Protopopescu C, Marcellin F, Rosellini S, Wittkop L, Esterle L, et al. Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients. J Hepatol. 2017;67:1157–67.  https://doi.org/10.1016/j.jhep.2017.08.005.CrossRefPubMedGoogle Scholar
  16. 16.
    Kronfli N, Bhatnagar SR, Hull MW, Moodie EEM, Cox J, Walmsley S, et al. Trends in cause-specific mortality in HIV–hepatitis C coinfection following hepatitis C treatment scale-up. AIDS. 2019;33:1013–22.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Costiniuk CT, Brunet L, Rollet-Kurhajec KC, Cooper CL, Walmsley SL, Gill MJ, et al. Tobacco smoking is not associated with accelerated liver disease in human immunodeficiency virus-hepatitis C coinfection: a longitudinal cohort analysis. In: Open Forum Infectious Diseases; 2016. p. ofw050.Google Scholar
  18. 18.
    Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol. 2014;28:753–70.CrossRefPubMedGoogle Scholar
  19. 19.
    Osna NA, Donohue TM, Kharbanda KK. Alcoholic liver disease: pathogenesis and current management. Alcohol Res. 2017;38:147–61.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Lackner C, Tiniakos D. Fibrosis and alcohol-related liver disease. J Hepatol. 2019;70:294–304.  https://doi.org/10.1016/j.jhep.2018.12.003.CrossRefPubMedGoogle Scholar
  21. 21.
    Eyawo O, McGinnis KA, Justice AC, Fiellin DA, Hahn JA, Williams EC, et al. Alcohol and mortality: combining self-reported (AUDIT-C) and biomarker detected (PEth) alcohol measures among HIV infected and uninfected. J Acquir Immune Defic Syndr. 2018;77:135–43.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Bravi F, Bosetti C, Tavani A, Gallus S, La Vecchia C. Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. Clin Gastroenterol Hepatol. 2013;11:1413–21.  https://doi.org/10.1016/j.cgh.2013.04.039.CrossRefPubMedGoogle Scholar
  23. 23.
    Carrieri MP, Serfaty L, Vilotitch A, Winnock M, Poizot-Martin I, Loko MA, et al. Cannabis use and reduced risk of insulin resistance in HIV-HCV infected patients: a longitudinal analysis (ANRS CO13 HEPAVIH). Clin Infect Dis. 2015;61:40–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Nordmann S, Vilotitch A, Roux P, Esterle L, Spire B, Marcellin F, et al. Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus-co-infected patients (ANRS CO13-HEPAVIH). J Viral Hepat. 2018;25:171–9.  https://doi.org/10.1111/jvh.12797.CrossRefPubMedGoogle Scholar
  25. 25.
    Penner EA, Buettner H, Mittleman MA. The impact of marijuana use on glucose, insulin, and insulin resistance among US adults. Am J Med. 2013;126:583–9.  https://doi.org/10.1016/j.amjmed.2013.03.002.CrossRefGoogle Scholar
  26. 26.
    Wijarnpreecha K, Panjawatanan P, Ungprasert P. Use of cannabis and risk of advanced liver fibrosis in patients with chronic hepatitis C virus infection: a systematic review and meta-analysis. J Evid Based Med. 2018;11:272–7.  https://doi.org/10.1111/jebm.12317.CrossRefPubMedGoogle Scholar
  27. 27.
    Farooqui MT, Khan MA, Cholankeril G, Khan Z, Mohammed Abdul MK, Li AA, et al. Marijuana is not associated with progression of hepatic fibrosis in liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2019;31:149–56.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Loko M-A, Salmon D, Carrieri P, Winnock M, Mora M, Merchadou L, et al. The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006–2010. BMC Infect Dis. 2010;10:303.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Salmon-Ceron D, Cohen J, Winnock M, Roux P, Sadr FB, Rosenthal E, et al. Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients’ beliefs (ANRS CO13 HEPAVIH cohort, France). BMC Health Serv Res. 2012;12:59.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–25.CrossRefGoogle Scholar
  31. 31.
    Roux P, Lions C, Cohen J, Winnock M, Salmon-Céron D, Bani-Sadr F, et al. Impact of HCV treatment and depressive symptoms on adherence to HAART among HIV-HCV-coinfected patients: results from the ANRS-CO13-HEPAVIH cohort. Antivir Ther. 2014;19:171–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Fuhrer R, Rouillon F. La version française de l’échelle CES-D (Center for Epidemiologic Studies-Depression Scale). Description et traduction de l’échelle d’autoévaluation. Eur Psychiatry. 1989;4:163–6.Google Scholar
  33. 33.
    Bradley KA, McDonell MB, Bush K, Kivlahan DR, Diehr P, Fihn SD. The AUDIT Alcohol Consumption Questions (AUDIT-C). Arch Intern Med. 1998;158:1789–95.  https://doi.org/10.1097/00000374-199811000-00034.CrossRefPubMedGoogle Scholar
  34. 34.
    Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.  https://doi.org/10.1080/01621459.1999.10474144.CrossRefGoogle Scholar
  35. 35.
    Mukhopadhyay P, Rajesh M, Horváth B, Bátkai S, Park O, Tanashian G, et al. Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. Free Radic Biol Med. 2011;50:1368–81.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Brunet L, Moodie EEM, Rollet K, Cooper C, Walmsley S, Potter M, et al. Marijuana smoking does not accelerate progression of liver disease in HIV-hepatitis C coinfection: a longitudinal Cohort analysis. Clin Infect Dis. 2013;57:663–70.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Adejumo AC, Adegbala OM, Adejumo KL, Bukong TN. Reduced incidence and better liver disease outcomes among chronic HCV infected patients who consume cannabis. Can J Gastroenterol Hepatol. 2018.  https://doi.org/10.1155/2018/9430953.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Salmon D, Bani-Sadr F, Loko MA, Stitou H, Gervais A, Durant J, et al. Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: results from ANRS CO13 HEPAVIH. J Hepatol. 2012;56:862–8.  https://doi.org/10.1016/j.jhep.2011.11.009.CrossRefPubMedGoogle Scholar
  39. 39.
    Vara D, Salazar M, Olea-Herrero N, Guzmán M, Velasco G, Díaz-Laviada I. Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Cell Death Differ. 2011;18:1099–111.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Carrieri MP, Lions C, Sogni P, Winnock M, Roux P, Mora M, et al. Association between elevated coffee consumption and daily chocolate intake with normal liver enzymes in HIV-HCV infected individuals: results from the ANRS CO13 HEPAVIH cohort study. J Hepatol. 2014;60:46–53.  https://doi.org/10.1016/j.jhep.2013.08.014.CrossRefPubMedGoogle Scholar
  41. 41.
    Carrieri MP, Sogni P, Cohen J, Loko MA, Winnock M, Spire B, et al. Elevated coffee consumption and reduced risk of insulin resistance in HIV-HCV coinfected patients (HEPAVIH ANRS CO-13). Hepatology. 2012;56:2010.CrossRefPubMedGoogle Scholar
  42. 42.
    Klein MB, Rollet-Kurhajec KC, Moodie EEM, Yaphe S, Tyndall M, Walmsley S, et al. Mortality in HIV-hepatitis C co-infected patients in Canada compared to the general Canadian population (2003–2013). AIDS. 2014;28:1957–65.CrossRefPubMedGoogle Scholar
  43. 43.
    Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2018;68:25–32.  https://doi.org/10.1016/j.jhep.2017.08.030.CrossRefGoogle Scholar
  44. 44.
    Di Angelantonio E, Bhupathiraju SN, Wormser D, Gao P, Kaptoge S, de Gonzalez AB, et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet. 2016;388:776–86.  https://doi.org/10.1016/S0140-6736(16)30175-1.CrossRefPubMedGoogle Scholar
  45. 45.
    Kee CC, Sumarni MG, Lim KH, Selvarajah S, Haniff J, Tee GHH, et al. Association of BMI with risk of CVD mortality and all-cause mortality. Public Health Nutr. 2017;20:1226–34.CrossRefPubMedGoogle Scholar
  46. 46.
    Park D, Lee J-H, Han S. Underweight: another risk factor for cardiovascular disease? A cross-sectional 2013 Behavioral Risk Factor Surveillance System (BRFSS) study of 491,773 individuals in the USA. Medicine. 2017;96:e8769.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Laugesen K, Baggesen LM, Schmidt SAJ, Glymour MM, Lasgaard M, Milstein A, et al. Social isolation and all-cause mortality: a population-based cohort study in Denmark. Sci Rep. 2018;8:4731.  https://doi.org/10.1038/s41598-018-22963-w.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Thomson H, Thomas S, Sellstrom E, Petticrew M. Housing improvements for health and associated socio-economic outcomes. Cochrane Database Syst Rev. 2013;28:008657.Google Scholar
  49. 49.
    Justice AC, McGinnis KA, Tate JP, Braithwaite RS, Bryant KJ, Cook RL, et al. Risk of mortality and physiologic injury evident with lower alcohol exposure among HIV infected compared with uninfected men. Drug Alcohol Depend. 2016;161:95–103.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Marcellin P, Pequignot F, Delarocque-Astagneau E, Zarski JP, Ganne N, Hillon P, et al. Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol. 2008;48:200–7.CrossRefPubMedGoogle Scholar
  51. 51.
    Roux P, Cohen J, Lascoux-Combe C, Sogni P, Winnock M, Salmon-Ceron D, et al. Determinants of the underreporting of alcohol consumption by HIV/HCV co-infected patients during face-to-face medical interviews: the role of the physician. Drug Alcohol Depend. 2011;116:228–32.  https://doi.org/10.1016/j.drugalcdep.2010.09.025.CrossRefPubMedGoogle Scholar
  52. 52.
    Lopez-Pelayo H, Batalla A, Balcells MM, Colom J, Gual A. Assessment of cannabis use disorders: a systematic review of screening and diagnostic instruments. Psychol Med. 2015;45:1121–33.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Melina Erica Santos
    • 1
    • 2
    • 3
  • Camelia Protopopescu
    • 2
    • 3
  • Philippe Sogni
    • 4
    • 5
    • 6
  • Issifou Yaya
    • 2
    • 3
  • Lionel Piroth
    • 7
    • 8
  • François Bailly
    • 9
    • 10
  • Fabienne Marcellin
    • 2
    • 3
  • Laure Esterle
    • 11
  • Linda Wittkop
    • 11
    • 12
  • Eric Rosenthal
    • 13
    • 14
  • Philippe Morlat
    • 15
  • Perrine Roux
    • 2
    • 3
  • Wildo Navegantes de Araujo
    • 16
  • Dominique Salmon-Ceron
    • 6
    • 17
  • Maria Patrizia Carrieri
    • 2
    • 3
    Email author
  • the ANRS CO13 HEPAVIH Study Group
  1. 1.Faculdade de Ciências da SaúdeUniversidade de BrasíliaBrasíliaBrazil
  2. 2.INSERM, IRD, SESSTIM, Sciences Economiques, & Sociales de la Santé & Traitement de l’Information Médicale, Aix Marseille UniversitéMarseilleFrance
  3. 3.Observatoire régional de la santé Provence-Alpes-Côte d’Azur, ORS PACAMarseilleFrance
  4. 4.Service d’HépatologieHôpital Cochin, AP-HPParisFrance
  5. 5.INSERM U-1223, Institut PasteurParisFrance
  6. 6.Université Paris Descartes - Sorbonne Paris CitéParisFrance
  7. 7.Département d’InfectiologieCHU de DijonDijonFrance
  8. 8.INSERM - CIC 1342, Université de BourgogneDijonFrance
  9. 9.Service d’Hépatologie et GastroentérologieHôpital de la Croix-RousseLyonFrance
  10. 10.INSERM U1052, Centre de Recherche en Cancérologie de LyonLyonFrance
  11. 11.Bordeaux Population Health Research Center, INSERM U1219, CIC-EC 1401, Univ. Bordeaux - ISPEDBordeauxFrance
  12. 12.Service d’information médicaleCHU de BordeauxBordeauxFrance
  13. 13.Service de Médecine InterneHôpital l’Archet, CHU de NiceNiceFrance
  14. 14.LAMHESS, Université de Nice-Sophia AntipolisNiceFrance
  15. 15.Service de Médecine Interne et Maladies InfectieusesCHU de BordeauxBordeauxFrance
  16. 16.Faculdade UnB CeilândiaUniversidade de BrasíliaBrasíliaBrazil
  17. 17.Service de Maladies Infectieuses et TropicalesHôpital Cochin, AP-HPParisFrance

Personalised recommendations